TY - JOUR
T1 - Doxorubicin-loaded graphene oxide nanocomposites in cancer medicine
T2 - Stimuli-responsive carriers, co-delivery and suppressing resistance
AU - Ashrafizadeh, Milad
AU - Saebfar, Hamidreza
AU - Gholami, Mohammad Hossein
AU - Hushmandi, Kiavash
AU - Zabolian, Amirhossein
AU - Bikarannejad, Pooria
AU - Hashemi, Mehrdad
AU - Daneshi, Salman
AU - Mirzaei, Sepideh
AU - Sharifi, Esmaeel
AU - Kumar, Alan Prem
AU - Khan, Haroon
AU - Heydari Sheikh Hossein, Hamid
AU - Vosough, Massoud
AU - Rabiee, Navid
AU - Thakur Kumar, Vijay
AU - Makvandi, Pooyan
AU - Mishra, Yogendra Kumar
AU - Tay, Franklin R
AU - Wang, Yuzhuo
AU - Zarrabi, Ali
AU - Orive, Gorka
AU - Mostafavi, Ebrahim
PY - 2022/2/14
Y1 - 2022/2/14
N2 - Introduction: The application of doxorubicin (DOX) in cancer therapy has been limited due to its drug resistance and poor internalization. Graphene oxide (GO) nanostructures have the capacity for DOX delivery while promoting its cytotoxicity in cancer. Areas covered: The favorable characteristics of GO nanocomposites, preparation method, and application in cancer therapy are described. Then, DOX resistance in cancer, GO-mediated photothermal therapy, and DOX delivery for cancer suppression are described. Preparation of stimuli-responsive GO nanocomposites, surface functionalization, hybrid nanoparticles, and theranostic applications are emphasized in DOX chemotherapy. Expert opinion: GO nanoparticle-based photothermal therapy maximizes the anti-cancer activity of DOX against cancer cells. Besides DOX delivery, GO nanomaterials are capable of loading anti-cancer agents and genetic tools to minimize drug resistance and enhance the cytolytic impact of DOX in cancer eradication. To enhance DOX accumulation, stimuli-responsive (redox-, light-, enzyme- and pH-sensitive) GO nanoparticles have been developed for DOX delivery. Development of targeted delivery of DOX-loaded GO nanomaterials against cancer cells may be achieved by surface modification of polymers such as polyethylene glycol, hyaluronic acid, and chitosan. DOX-loaded GO nanoparticles have demonstrated theranostic potential. Hybridization of GO with other nanocarriers such as silica and gold nanoparticles further broadens their potential anti-cancer therapy applications.
AB - Introduction: The application of doxorubicin (DOX) in cancer therapy has been limited due to its drug resistance and poor internalization. Graphene oxide (GO) nanostructures have the capacity for DOX delivery while promoting its cytotoxicity in cancer. Areas covered: The favorable characteristics of GO nanocomposites, preparation method, and application in cancer therapy are described. Then, DOX resistance in cancer, GO-mediated photothermal therapy, and DOX delivery for cancer suppression are described. Preparation of stimuli-responsive GO nanocomposites, surface functionalization, hybrid nanoparticles, and theranostic applications are emphasized in DOX chemotherapy. Expert opinion: GO nanoparticle-based photothermal therapy maximizes the anti-cancer activity of DOX against cancer cells. Besides DOX delivery, GO nanomaterials are capable of loading anti-cancer agents and genetic tools to minimize drug resistance and enhance the cytolytic impact of DOX in cancer eradication. To enhance DOX accumulation, stimuli-responsive (redox-, light-, enzyme- and pH-sensitive) GO nanoparticles have been developed for DOX delivery. Development of targeted delivery of DOX-loaded GO nanomaterials against cancer cells may be achieved by surface modification of polymers such as polyethylene glycol, hyaluronic acid, and chitosan. DOX-loaded GO nanoparticles have demonstrated theranostic potential. Hybridization of GO with other nanocarriers such as silica and gold nanoparticles further broadens their potential anti-cancer therapy applications.
KW - Anti-cancer chemotherapy
KW - carbon nanomaterials
KW - doxorubicin
KW - drug resistance
KW - graphene oxide
KW - stimuli-responsive
UR - http://www.scopus.com/inward/record.url?scp=85127130806&partnerID=8YFLogxK
U2 - 10.1080/17425247.2022.2041598
DO - 10.1080/17425247.2022.2041598
M3 - Review article
C2 - 35152815
VL - 19
SP - 355
EP - 382
JO - Expert Opinion on Drug Delivery
JF - Expert Opinion on Drug Delivery
SN - 1742-5247
IS - 4
ER -
